In:
Journal of Viral Hepatitis, Wiley, Vol. 25, No. 12 ( 2018-12), p. 1533-1542
Abstract:
There is a paucity of information on chronic hepatitis C ( CHC ) patients treated with direct antiviral agents ( DAA s) in Asia. We invited Asia‐Pacific physicians to collate databases of patients enrolled for CHC treatment, recording baseline clinical, virologic and biochemical characteristics, sustained virologic response at week 12 ( SVR 12) and virologic failure. SVR 12 outcome was based on intention to treat ( ITT ). Multivariate analysis was used to assess independent risk factors for SVR 12 using SPSS version 20. A total of 2171 patients from India (n = 977), Myanmar (n = 552), Pakistan (n = 406), Thailand (n = 139), Singapore (n = 72) and Malaysia (n = 25) were collected. At baseline, mean age was 49 years, 50.2% were males, and 41.8% had cirrhosis. Overall, SVR 12 was 89.5% and by genotype ( GT ) based on ITT and treatment completion, respectively, was 91% and 92% for GT 1, 100% and 100% for GT 2, 91% and 97% for GT 3, 64% and 95% for GT 4, 87% and 87% for GT 6 and 79% and 91% for GT untested. Patients with cirrhosis had SVR 12 of 85% vs 93% for noncirrhosis ( P 〈 0.001) ( RR 2.1, 95% CI 1.4‐3.1, P = 0.0002). Patients with GT 1 and GT 3 treated with sofosbuvir/ribavirin ( SR ) had 88% and 89% SVR 12, respectively, but those GT 6 treated with sofosbuvir/ledipasvir ( SL ) had only 77.6% SVR 12. Multivariate analysis showed absence of cirrhosis was associated with higher SVR 12 ( OR 2.0, 95% CI 1.3‐3.1, P = 0.002). In conclusion, patients with GT 1 and GT 3 with/without cirrhosis had surprisingly high efficacy using SR , suggesting that Asians may respond better to some DAA s. However, poor GT 6 response to SL suggests this regimen is suboptimal for this genotype.
Type of Medium:
Online Resource
ISSN:
1352-0504
,
1365-2893
DOI:
10.1111/jvh.2018.25.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2007924-2
Permalink